More UK women are trying CBD topicals and suppositories for menstrual and pelvic pain, but the FSA’s 10 mg/day advice and emerging 2024–2026 evidence call for caution. This article summarises current observational findings, regulatory guidance, safety considerations including potential drug interactions, and practical 'start low, go slow' steps for those considering topical routes.

This article summarises UK and international evidence (2020–2026) on low‑dose CBD for adults with ADHD: what registry analyses, small trials and systematic reviews tell us about efficacy, dosing bands, safety and drug interactions, and the practical workplace guidance gap.

This article reviews 2022–2026 evidence on whether low‑dose (microdosed) CBD might support night‑shift sleep for NHS staff. It covers trial applicability, variable timing (Tmax), drug interactions (notably with clobazam, some antidepressants and opioids), driving safety and the workplace drug‑testing gap, and gives practical steps for staff considering CBD.